Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells

Leukemia Research

Volumn 20, Issue 8, 1996, Pages 657-664

  Davey, Mary W ^a   Hargrave, Rebecca M ^a   Davey, Ross A ^b  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Daunorubicin; Idarubicin; Multidrug resistance (MDR); Multidrug resistance associated protein (MRP); P glycoprotein; Rhodamine 123

Indexed keywords

BUTHIONINE SULFOXIMINE; DAUNORUBICIN; GLYCOPROTEIN P; IDARUBICIN; RHODAMINE 123; VALSPODAR; VERAPAMIL;

ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0030221523     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(96)00023-9     Document Type: Article

References (33)

1. 1. Gottesman M. M. & Pastan I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 62, 385.
2. 2. Cole S. P., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M. & Deeley R. G. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650.
3. 3. Barrand M. A., Heppel-Parton A. C. Wright K. A., Rabbits P. H. & Twentyman P. R. (1994) A 190k protein overexpressed in non-P-glycoprotein containing MDR cells and its relation to the MRP gene. J. Natl Cancer Inst. 86, 110.
4. 4. Krishnamachary N., Ma L., Zheng L., Safa A. R. & Center M. S. (1994) Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. Oncol. Res. 6, 119.
5. 5. Barrand M. A., Rhodes T., Center M. S. & Twentyman P. R. (1993) Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190 k membrane protein distinct from P-glycoprotein. Eur. J. Cancer 29A, 408.
6. 6. Van der Heyden S., Gheuens E., Debruijn E., Vanoosterom A. & Maes R. (1995) P-glycoprotein - clinical significance and methods of analysis. Crit. Rev. Clin. Lab. Sci. 32, 221.
7. 7. Nussler V., Pelka-Fleischer R., Zwierzina H., Nerl C., Beckert B., Gullis E., Gieseler F., Bock S., Bartl R., Petrides P. E. & Wilmanns W. (1994) Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes - first experience with their reversal. Ann. Hematol. 69, S25.
8. 8. Burger H., Nooter K., Zaman G. J., Sonneveld P., Wingerden K. E. van, Oostrum R. G. & Stoter G. (1994) Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 8, 990.
9. 9. Burger H., Nooter K., Sonneveld P., Van Windergerden K. E. & Zaman G. J. R. (1994) High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia. Br. J. Haemat. 88, 348.
10. 10. Nussler V., Giesler F., Pelka-Fleischer R., Gullis E., Abendhardt W., Langenmayer I., Heinemann V., Kolb H. J. & Wilmanns W. (1994) Reversal of P-glycoprotein related resistance by idarubicin. Bone Marrow Transplant. 12, S162.
11. 11. Berman E. (1993) A review of idarubicin in acute leukemia. Oncology 7, 91.
12. 12. Bellamy W. T. & Dalton W. S. (1994) Multidrug resistance in the laboratory and clinic. Adv. Clin. Chem. 31, 1.
13. 13. Twentyman P. R. (1992) Cyclosporins as drug resistance modifiers. Biochem. Pharmacol. 43, 109.
14. 14. Collins H. L., Fisher G. A., Hausdorff J., Lum B. L., Pearce T., Halsey J. & Sikic B. I. (1995) Phase 1 trial of paclitaxel in combination with SDZ PSC 833, a multidrug resistance modifier. Proc. Am. Soc. Clin. Oncol. 14, 181.
15. 15. Hausdorff J., Fisher G. A., Halsey J., Collins H. L., Lum B. L., Brophy N. A., Duran G. E., Nix D., Pearce T. & Sikic B. I. (1995) A phase 1 trial of etoposide with the oral cyclosporin SDZ PSC 833, a modulator of multidrug resistance (MDR). Proc. Am. Soc. Clin. Oncol. 14, 181.
16. 16. Jiang X.-R., Kelsey S. M., Wu Y.-L. & Newland A. C. (1995) Circumvention of P-glycoprotein mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDS PSC 833. Br. J. Haemat. 90, 375.
17. 17. Boesch D., Gaveriaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P. & Loor F. (1991) In vivo circumvention of P-glycoprotein mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 51, 4226.
18. 18. Davey R. A., Longhurst T. J., Davey M. W., Belov L., Harvie R. M., Hancox D. & Wheeler H. (1995) Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line. Leukemia Res. 19, 275.
19. 19. Beck W., Mueller T. & Tanzer L. (1979) Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res. 39, 2060.
20. 20. Delville J.-P., Pradler O., Pauwels O., Van Onderbergen A., Kiss R., Feremans W. & Capel P. (1995) Comparative study of multidrug resistance evaluated by means of the quantitative immunohistochemical detection of P-glycoprotein and the functional release of rhodamine 123. Am. J. Haematol. 49, 183.
21. 21. Foley G., Lazarus H., Farber S., Uzman B., Boone B. & McCarthy R. (1965) Continuous culture of human lymphoblasts from peritoneal blood of a child with acute leukemia. Cancer 18, 522.
22. 22. Marks D. C., Belov L., Davey M. W., Davey R. A. & Kidman A. D. (1992) The MTT cell viability assay for cytotoxicity testing in multidrug resistant human leukemic cells. Leukemia Res. 16, 1165.
23. 23. Arceci R. J. (1993) Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81, 2215.
24. 24. Hargrave R. M., Davey M. W., Davey R. A. & Kidman A. D. (1995) Development of drug resistance is reduced with idarubicin relative to other anthracyclines. Anti-Cancer Drugs 6, 432.
25. 25. Toffoli G., Simone F., Gigante M. & Boiocchi M. (1994) Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines. Biochem. Pharmacol. 48, 1871.
26. 26. Longhurst T., Harvie R. M., Davey M. W. & Davey R. A. (1994) Multidrug resistance (MDR) mechanisms in epirubicin selected CCRF-CEM human leukaemia cells which overexpress MRP. Proc. Am. Assoc. Cancer Res. 35, 13.
27. 27. Versantvoort C. H. M., Broxterman H. J., Bagrij T., Scheper R. J. & Twentyman P. R. (1995) Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br. J. Cancer 72, 82.
28. 28. Goebel M. (1993) Oral idarubicin - an anthracycline derivative with unique properties. Hematology 66, 33.
29. 29. Ford J. M. & Hait W. N. (1990) Pharmacology of drugs that alter multidrug resistance. Pharmacol. Rev. 42, 155.
30. 30. Drori S., Eytan G. D. & Assaraf Y. G. (1995) Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur. J. Biochem. 228, 1020.
31. 31. Fukushima T., Ueda T., Uchida M. & Nakamura T. (1993) Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells. Int. J. Hemat. 57, 121.
32. 32. Scambia G., Benedetti Panici P., Contu G., Vincenzo R., Ferrandina G., Isola G., Maccio A. & Mancuso S. (1994) Mechanisms and modulation of resistance to anthracyclines (review). Int. J. Oncol. 4, 951.
33. 33. Marks D. C., Davey M. W., Davey R. A. & Kidman A. D. (1995) Expression of multidrug resistance in response to differentiation in the K562 human leukaemia cell line. Biochem. Pharmacol. 50, 475.